Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 65-72

  Nishikawa, Hiroki ^a   Osaki, Yukio ^a   Kita, Ryuichi ^a   Kimura, Toru ^a   Ohara, Yoshiaki ^a   Takeda, Haruhiko ^a   Sakamoto, Azusa ^a   Saito, Sumio ^a   Nishijima, Norihiro ^a   Nasu, Akihiro ^a   Komekado, Hideyuki ^a   Nishiguchi, Shuhei ^b  

^a OSAKA RED CROSS HOSPITAL   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Clinical outcome; Intermediate stage hepatocellular carcinoma; Trans catheter arterial chemoembolization; Transcatheter arterial chemotherapy infusion; Treatment efficacy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN; PROTHROMBIN;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TRANSCATHETER ARTERIAL CHEMOTHERAPY INFUSION; TREATMENT RESPONSE; TUMOR VOLUME; ULTRASOUND;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; EPIRUBICIN; ETHIODIZED OIL; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MITOMYCIN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84891958503     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2845     Document Type: Article

References (36)

1. de Lope CR, Tremosini S, Forner A, Reig M and Bruix J: Management of HCC. J Hepatol 56 (Suppl 1): S75-S87, 2012.
2. Livraghi T, Mäkisalo H and Line PD: Treatment options in hepatocellular carcinoma today. Scand J Surg 100: 22-29, 2011.
3. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273, 2012.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
5. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M and Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
7. Wigg AJ, Palumbo K and Wigg DR: Radiotherapy for hepatocellular carcinoma: systematic review of radiobiology and modeling projections indicate reconsideration of its use. J Gastroenterol Hepatol 25: 664-671, 2010.
8. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T and Spreafico C: Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 57: 1826-1837, 2013.
9. Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A and Lee C: Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 197: W562-W570, 2011.
10. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y and Chung H: Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 78 (Suppl 1): 148-153, 2010.
11. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M and Makuuchi M; Liver Cancer Study Group of Japan: Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 194: 830-837, 2010.
12. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M and Makuuchi M: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131: 461-469, 2006.
13. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J and Bruix J; Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739, 2002.
14. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST and Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002.
15. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A and Cottone M: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224: 47-54, 2002.
16. Bruix J and Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
17. Bruix J and Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022, 2011.
18. Nishikawa H, Osaki Y, Kita R and Kimura T: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. Cancers 4: 165-183, 2012.
19. Nishikawa H, Osaki Y, Kita R, Kimura T, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S and Nasu A: Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol 41: 903-909, 2012.
20. Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T and Osaki Y: Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma. Int J Oncol 42: 151-160, 2013.
21. Intra-arterial administration of epirubicin in the treatment of nonresectable hepatocellular carcinoma. Epirubicin Study Group for Hepatocellular Carcinoma. Cancer Chemother Pharmacol 19: 183-189, 1987.
22. Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, Matsuda F, Eso Y, Ishikawa T, Saito S, Kita R, Kimura T and Osaki Y: Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol 46: 1418-1426, 2011.
23. Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T and Kadoya M: Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 225: 143-149, 2002.
24. Satake M, Uchida H, Arai Y, Anai H, Sakaguchi H, Nagata T, Yamane T, Kichikawa K, Osaki Y, Okazaki M, Higashihara H, Nakamura H, Osuga K, Nakao N and Hirota S: Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovasc Intervent Radiol 31: 756-761, 2008.
25. Minami Y and Kudo M: Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: ultrasonography, CT and MR imaging. Oncology 84 (Suppl 1): 58-63, 2013.
26. Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, Furuse J, Nakamura K and Makuuchi M; Liver Cancer Study Group of Japan (Committee for Response Evaluation Criteria in Cancer of the Liver, Liver Cancer Study Group of Japan). Hepatol Res 40: 686-692, 2010.
27. Imaeda T, Yamawaki Y, Seki M, Goto H, Iinuma G, Kanematsu M, Mochizuki R, Doi H, Saji S and Shimokawa K: Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology. Cardiovasc Intervent Radiol 16: 209-213, 1993.
28. Jun CH, Ki HS, Lee HK, Park KJ, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK and Rew JS: Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. World J Gastroenterol 19: 284-289, 2013.
29. Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, Osaki Y, Sata M, Fujiyama S, Kumada T, Sato K, Yamamoto S, Hinotsu S and Sato T: Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol 51: 1030-1036, 2009.
30. Ikeda M, Maeda S, Shibata J, Muta R, Ashihara H, Tanaka M, Fujiyama S and Tomita K: Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 66: 24-31, 2004.
31. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L and Lencioni R: Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 37: 212-220, 2011.
32. Ishikawa T: Future perspectives on the treatment of hepatocellular carcinoma with cisplatin. World J Hepatol 1: 8-16, 2009.
33. Nishikawa H and Osaki Y: Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. Hepatol Res: Jul 2, 2013. doi: 10.1111/hepr.12194 (Epub ahead of print).
34. Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, Satake M, Arai Y and Okusaka T: Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. J Gastroenterol: Jun 23, 2013. (Epub ahead of print).
35. Poon RT, Fan ST, Lo CM, Liu CL, Ngan H, Ng IO and Wong J: Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. Am J Gastroenterol 94: 2460-2466, 1999.
36. Yau T, Yao TJ, Chan P, Epstein RJ, Ng KK, Chok SH, Cheung TT, Fan ST and Poon RT: The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization. Cancer 115: 5507-5515, 2009.